MindWalk Holdings Corp. (NASDAQ:HYFT) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Shares of MindWalk Holdings Corp. (NASDAQ:HYFT) have received an average recommendation of “Moderate Buy” from the five research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $5.00.

A number of analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of MindWalk in a research note on Tuesday. Zacks Research upgraded shares of MindWalk from a “strong sell” rating to a “hold” rating in a report on Monday, September 21st. Wall Street Zen raised shares of MindWalk from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, HC Wainwright reiterated a “buy” rating on shares of MindWalk in a report on Monday, July 20th.

MindWalk Trading Down 7.4%

HYFT opened at $1.37 on Thursday. The business has a fifty day moving average of $1.37 and a 200 day moving average of $1.39. MindWalk has a 52-week low of $0.99 and a 52-week high of $2.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.75 and a current ratio of 1.84.

MindWalk (NASDAQ:HYFT) last announced its quarterly earnings data on Monday, September 14th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.04). MindWalk had a negative net margin of 105.11% and a negative return on equity of 133.26%. The business had revenue of $2.73 million during the quarter, compared to the consensus estimate of $3.25 million. As a group, equities analysts predict that MindWalk will post -0.28 EPS for the current fiscal year.

Hedge Funds Weigh In On MindWalk

An institutional investor recently bought a new position in MindWalk stock. GSA Capital Partners LLP purchased a new stake in shares of MindWalk Holdings Corp. (NASDAQ:HYFT) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 34,525 shares of the company’s stock, valued at approximately $55,000. GSA Capital Partners LLP owned approximately 0.07% of MindWalk as of its most recent filing with the Securities & Exchange Commission. 6.70% of the stock is owned by institutional investors.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.